Introduction: AD-DS, the most common genetic form of AD {#s1}
=======================================================

Down syndrome (DS) is a complex, heterogeneous disorder caused by the presence of an extra copy of human chromosome 21. Trisomy 21 is a common condition, with an incidence of 1 in 750 live births (Parker et al., [@B191]). Prevalence in many countries is growing due to increasing maternal age, the greatest risk factor for DS (Loane et al., [@B149]), together with rises in DS life expectancy (Yang et al., [@B287]; Bittles and Glasson, [@B13]). In Northern Europe, for example, the number of people aged over 40 years with DS is approximately double what it was in 1990, and in the UK this age group accounts for a third of the estimated 40,000 people with DS (Wu and Morris, [@B285]).

The clinical presentation of DS varies extensively and includes features present in all individuals, such as cognitive deficits, and those seen in only some people, such as heart defects (Zigman, [@B295]; Jensen and Bulova, [@B121]). Alzheimer disease (AD) pathology is found in the brains of virtually all people with DS by 40 years of age (Wisniewski et al., [@B281]; Mann and Esiri, [@B159]), and trisomy 21 causes an increased risk of dementia such that approximately one third of the DS population has AD ("AD-DS") by the age of 60, with an estimated lifetime prevalence of 90% for all people with DS (Prasher and Krishnan, [@B206]; Holland et al., [@B104]; Coppus et al., [@B49]; Margallo-Lana et al., [@B162]; McCarron et al., [@B166]). However, while AD-DS is one of the largest contributors to morbidity and mortality in DS (Coppus et al., [@B50]), not all individuals develop dementia, even by 70 years of age (Krinsky-McHale et al., [@B133]; Ghezzo et al., [@B83]). Thus, the DS population has the most common genetic form of early-onset AD, caused by trisomy 21. Studying AD-DS allows investigation of the initial pathogenic events leading to AD and the development of dementia, relevant to both people with DS and to the general population.

One approach to dissecting human disease is through studying mouse models, and a large number of transgenic strains have been generated to understand specific aspects of AD pathology, most of which have human gene mutations that give rise to rare early-onset familial Alzheimer disease (FAD; Braidy et al., [@B21]; Webster et al., [@B273]). In the last decade, chromosome engineering techniques have enabled the generation of an array of DS mouse models that will allow us to dissect the genetic contribution of chromosome 21 (Hsa21), or regions of the mouse genome syntenic to Hsa21, to DS phenotypes. These models recapitulate a wide range of DS features, including neurobiological, behavioral and aging-related aspects (Zhang et al., [@B293]; Ruparelia et al., [@B216]). Thus, in the study of AD-DS, mouse models of DS offer an increasingly important approach to understanding pathogenic mechanisms, so informing us about pathways and networks relevant to all populations at risk of dementia.

Here, we present an overview of clinical features of AD-DS, compared to other genetic forms of AD, to highlight human phenotypes that may be assessed in mechanistic studies of mouse models. We then give examples of data from DS mouse models compared to transgenic mice modeling aspects of AD pathology, to illustrate informative findings from both types of model. We also offer examples of potentially helpful data for investigating AD-DS from the outcomes of overexpressing single genes from Hsa21. Finally, we consider the important features for mouse models to enhance our understanding of AD-DS, and therefore the pathogenetic mechanisms relevant to all AD. For brevity, citations may not necessarily be the original papers, but useful reviews or later references.

Genetic forms of AD, including AD-DS {#s2}
====================================

The *APP* gene lies on Hsa21 and encodes the amyloid precursor protein that is at the heart of the amyloid cascade hypothesis of Alzheimer disease (Glenner and Wong, [@B84]; Hardy and Higgins, [@B96]; Hardy and Selkoe, [@B95]). This hypothesis was generated partly from the observation that extracellular plaques in brains of people with AD are composed of Aβ peptides that are products of APP metabolism. The hypothesis suggests that abnormal APP metabolism initiates AD pathogenesis by triggering a set of events that result in Aβ aggregation, particularly of the Aβ42 peptide, in these extracellular plaques. This leads to the formation of intracellular neurofibrillary tangles, primarily composed of the protein tau, and eventually loss of synapses and neurons. The relationship between the histopathological features of AD and dementia is not yet clear (Castellani and Perry, [@B32]).

The amyloid cascade hypothesis is currently the most widely-accepted paradigm guiding investigations of AD pathogenesis, and is supported at least in part by the rare cases of FAD caused by different mutations in *APP*, and in the presenilin genes *PSEN1* and *PSEN2* that affect APP processing. *APP* mutations may, for example, result in an increase in total Aβ production, or a relative increase in Aβ species associated with pathogenicity (Ryan and Rossor, [@B218]).

Importantly for understanding AD-DS, the link between *APP* and AD also extends to gene dose: in rare forms of FAD, duplication of the wildtype *APP* locus alone ("Dup-APP") is sufficient to cause highly penetrant early-onset AD (Rovelet-Lecrux et al., [@B214]; Sleegers et al., [@B247]). Dup-APP cases demonstrate that the three doses of *APP* arising from trisomy 21 are likely to be causative for AD-DS. Conversely, although very rare, partial trisomy 21 excluding *APP* (i.e., with two "doses" of *APP*) does not appear to lead to AD (Prasher et al., [@B205]; Korbel et al., [@B130]).

While people with DS and Dup-APP are at high risk of dementia, presumably in both cases because of *APP* triplication, there are some intriguing differences in their AD-related clinical features (Wiseman et al., [@B280]). Examining the effects of different *APP* genotypes may therefore provide insights into the modulation of *APP* pathogenesis. Table [1](#T1){ref-type="table"} shows key examples of phenotypes in AD-DS and how these compare with Dup-APP, FAD due to other *APP* mutations (primarily point mutations) and late-onset sporadic AD (SAD). Mutations in *PSEN1* and *PSEN2*, which do not map to Hsa21, are not included.

###### 

**Comparison of phenotypes from different genetic forms of human Alzheimer disease**.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Phenotype**                                     **AD-DS: three copies of wildtype *APP***                                                                                                                                                  **FAD (Dup-APP): three copies of wildtype *APP***                                                                                                                                                                                                                                                                      **FAD (*APP* mutations): Usually heterozygous for a mutant *APP* allele. *N.B. these mutations do not necessarily act by the same mechanisms***          **SAD: two copies of wildtype *APP***                                                                                                                                                                                                                                                  
  ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **CLINICAL SYMPTOMS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Cognition                                         Incidence and age of onset of dementia                                                                                                                                                     Less than 40 years of age, \< 5% people with DS have dementia but prevalence doubles every 5 years; by 55--60 years, 50--70% of DS have AD (Tyrrell et al., [@B261]; Hartley et al., [@B97])                                                                                                                           Dementia onset \~42--59 years of age (Cabrejo et al., [@B28])                                                                                            Dementia onset \~45--60 years of age (Ryan and Rossor, [@B218])                                                                                                                                                                                                                        Dementia onset usually \>65 years of age (Querfurth and LaFerla, [@B208])

                                                                                                                                                                                                                                               Total prevalence across lifespan estimated at \~90% (McCarron et al., [@B166])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                    Pre-clinical cognitive symptoms                                                                                                                                                            Pre-existing cognitive impairments complicate diagnosis of AD in DS (Zigman, [@B295])                                                                                                                                                                                                                                  No apparent pre-symptomatic cognitive impairment (Cabrejo et al., [@B28]; Rovelet-Lecrux et al., [@B214])                                                Pre-symptomatic impairment of verbal memory and IQ; early progressive impairment of episodic memory (Rovelet-Lecrux et al., [@B214]; Hooli et al., [@B106])                                                                                                                            Mild cognitive impairment (cognitive symptoms, notably memory problems, which do not significantly affect function) precedes dementia (Albert et al., [@B2]), although only 5--20% go on to develop dementia

                                                                                                                                                                                                                                               Memory deficits may occur up to 3 years before dementia diagnosis (Krinsky-McHale et al., [@B134])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                    Clinical presentation of dementia                                                                                                                                                          Amnestic presentation similar to AD after taking into account pre-existing baseline intellectual deficits                                                                                                                                                                                                              Slow and progressive memory impairment and loss of cognition (Sleegers et al., [@B247])                                                                  Most cases have similar amnestic presentation to SAD (Pilotto et al., [@B199])                                                                                                                                                                                                         Progressive deficits in episodic memory, semantic knowledge, working memory, and attention (Weintraub et al., [@B276])

                                                                                                                                                                                                                                               However, changes in behavior and personality are more common than SAD (Krinsky-McHale et al., [@B135]; Devenny et al., [@B64]; Ball et al., [@B8])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                    Sex differences                                                                                                                                                                            No difference between sexes (Coppus et al., [@B49])                                                                                                                                                                                                                                                                    Not reported                                                                                                                                             Not reported                                                                                                                                                                                                                                                                           Women at higher risk (Musicco, [@B181])

  Epilepsy                                                                                                                                                                                                                                     Up to 84% AD-DS experience seizures (Mendez and Lim, [@B170]; De Simone et al., [@B59])                                                                                                                                                                                                                                Up to 57% exhibit seizures (Rovelet-Lecrux et al., [@B214])                                                                                              Seizures described in at least four different APP mutations (Kumar-Singh et al., [@B136]; Murrell et al., [@B180]; Grabowski et al., [@B87]; Pasalar et al., [@B193])                                                                                                                  Up to 10--20% of patients exhibit seizures (Mendez and Lim, [@B170]; Palop, [@B189])

  **CLASSICAL AD NEUROPATHOLOGY: Aβ** **AND TAU**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Aβ accumulation and deposition                    Intracellular Aβ                                                                                                                                                                           Intraneuronal accumulation of Aβ42 has been seen at 3 years of age. Levels decline as diffuse and dense core plaques develop (Mori et al., [@B176])                                                                                                                                                                    Intraneuronal accumulation of Aβ40 in post mortem brain. No intraneuronal Aβ42 detected (Cabrejo et al., [@B28])                                         Not reported                                                                                                                                                                                                                                                                           Intracellular staining found in post mortem SAD tissue (LaFerla et al., [@B137])

                                                    Extracellular Aβ                                                                                                                                                                           Earliest extracellular deposition found at 8 years of age (Leverenz and Raskind, [@B144])\                                                                                                                                                                                                                             Parenchymal lesions predominantly composed of Aβ42. Vascular amyloid predominantly Aβ40 (Cabrejo et al., [@B28]; Rovelet-Lecrux et al., [@B214])\        Increased Aβ42/Aβ40 ratio and/or increased Aβ production (Tanzi, [@B258]). Rare APP A673T mutant confers protection against AD pathology (Peacock et al., [@B194]; Hashimoto and Matsuoka, [@B98])\                                                                                    Accumulation of Aβ42 and Aβ40 into amyloid plaques. Aβ42 is more abundant in plaques (Serrano-Pozo et al., [@B235])\
                                                                                                                                                                                                                                               \                                                                                                                                                                                                                                                                                                                      \                                                                                                                                                        \                                                                                                                                                                                                                                                                                      \
                                                                                                                                                                                                                                               Aβ40 undetectable in plaques in DS brain \< 50 years of age. Proportion of Aβ40 in plaques gradually increases until =50 years of age 42% of dense-core plaques comprise of Aβ40 (Iwatsubo et al., [@B117]) Amyloid plaques universal in DS people by age 31 (Leverenz and Raskind, [@B144]; Hartley et al., [@B97])   Abundant parenchymal and vascular lesions as both dense-core and diffuse plaques (Cabrejo et al., [@B28]; Guyant-Marechal et al., [@B92])                Pattern and progression of amyloid plaque deposition is largely identical to SAD. However, mutations within the Aβ sequence can cause increased deposition in the vasculature (Pilotto et al., [@B199])                                                                                Amyloid plaque deposition progresses in a stereotypical fashion characterized by Thal phases I-V (Thal et al., [@B259])\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Highest accumulation of plaques found in layers II--IV of the isocortex (Braak and Braak, [@B20]; Serrano-Pozo et al., [@B235])

                                                    Cerebral Amyloid Angiopathy (CAA) and Intra-cranial Hemorrhage (ICH)                                                                                                                       CAA pathology common in DS. ICH is rare (Mann, [@B160]; McCarron et al., [@B167]; Naito et al., [@B183])                                                                                                                                                                                                               CAA is ubiquitous (Cabrejo et al., [@B28]; Sleegers et al., [@B247]; Rovelet-Lecrux et al., [@B213]; Kasuga et al., [@B123])\                            CAA is in a large number of FAD mutations but not all (Ryan and Rossor, [@B218])\                                                                                                                                                                                                      \~50--80% of cases have CAA, deposits primarily composed of Aβ40 (Jellinger et al., [@B120]; Serrano-Pozo et al., [@B235])\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \                                                                                                                                                        \                                                                                                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ICH in 20--50% of cases (Cabrejo et al., [@B28]; Rovelet-Lecrux et al., [@B213]; Guyant-Marechal et al., [@B92]; Kasuga et al., [@B123])                 Arctic and Dutch APP mutations both affect residue 693 but only patients with Dutch mutation develop CAA and ICH (Basun et al., [@B9]; Ryan and Rossor, [@B218])                                                                                                                       ICH in \~3% of SAD cases, possibly related to hypertension (Jellinger et al., [@B120])

  Neurofibrillary tangles                           NFTs present in almost all people with DS by age 45. Density of NFTs triples between age 40--50 (Wisniewski et al., [@B281]; Goedert et al., [@B85])\                                      NFTs consistent with late stage AD present at time of death (Rovelet-Lecrux et al., [@B214])                                                                                                                                                                                                                           Different FAD mutations exert highly variable effects on NFTs, from absence of NFTs in Arctic mutations to severe pathology (Ryan and Rossor, [@B218])   Stereotypical spatiotemporal progression of NFTs begins in the allocortex of the medial temporal lobe with six stages of development, distinguished by Braak stages (Braak and Braak, [@B20])\                                                                                         
                                                    NFT density correlates more strongly with clinical dementia rating than Aβ plaque count (Margallo-Lana et al., [@B162])\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Increased levels of total tau and phospho-tau correlate with increase in SAD severity (Wallin et al., [@B270]; Serrano-Pozo et al., [@B235])                                                                                                                                           
                                                    NFTs only manifest subsequent to dense-core amyloid plaques (Hartley et al., [@B97])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Neuronal loss and brain atrophy                   Neuronal atrophy follows SAD pattern but trend for less relative cell loss and atrophy compared to SAD (Mann, [@B161])\                                                                    Diffuse cortical atrophy with parietal dominance and neuronal loss (Cabrejo et al., [@B28]; Sleegers et al., [@B247]; Rovelet-Lecrux et al., [@B213]; Guyant-Marechal et al., [@B92]; Kasuga et al., [@B123])                                                                                                          Similar neuronal atrophy pattern to SAD with a slightly more severe medial-temporal pattern (Pilotto et al., [@B199])                                    Characteristic loss of neurons and white matter (Querfurth and LaFerla, [@B208]). Neuronal loss correlates with NFTs (Gómez-Isla et al., [@B86]; Serrano-Pozo et al., [@B235]) Basal forebrain atrophy correlates with Aβ burden (Kerbler et al., [@B124])                             
                                                    Selective loss of BFCNs from as early as 5.5 months of age. Progressive loss of neurons in the Nucleus basalis of Meynert during aging (Casanova et al., [@B31]; McGeer et al., [@B168])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **OTHER FEATURES OF AD PATHOLOGY**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Synaptic loss and dysfunction                     Synaptic protein expression decreased in aging DS brain (Downes et al., [@B71])\                                                                                                           Not reported                                                                                                                                                                                                                                                                                                           Not reported                                                                                                                                             Synapse loss is best correlate of cognitive decline and precedes neuronal loss (Ingelsson et al., [@B114]; Scheff et al., [@B231])\                                                                                                                                                    
                                                    GABA levels decreased in post-mortem hippocampus and temporal cortex (Reynolds and Warner, [@B211]; Seidl et al., [@B233]; Martínez-Cué et al., [@B165])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   GABA significantly reduced in post mortem cortical but not subcortical brain regions. *In vivo* evidence of GABA loss in parietal cortex (Seidl et al., [@B233]; Bai et al., [@B6])                                                                                                    

  Oxidative stress and proteostasis                 Some proteins oxidatively modified differently in DS and control groups, suggesting DS subjects vulnerable to oxidative damage (Di Domenico et al., [@B67])                                Not reported                                                                                                                                                                                                                                                                                                           Not reported                                                                                                                                             Increased levels of oxidative stress are a hallmark of SAD pathology and linked to aging (Madeo, [@B157])                                                                                                                                                                              

  Endosomal dysfunction                             Endosome enlargement, alterations in morphology and function in young DS (pre-AD) and DS fibroblasts (Jiang et al., [@B122])                                                               Not reported                                                                                                                                                                                                                                                                                                           Enlarged endosomes modulated by ApoE status (Cataldo et al., [@B33])                                                                                     Enlarged endosomes detected in preclinical stages (Cataldo et al., [@B34], [@B36])\                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Aβ accumulates within late endosomes in AD brain (Takahashi et al., [@B255])                                                                                                                                                                                                           

  Neuroinflammation                                 Dystrophic microglia and absence of activated microglia at 40 years of age, coincident with tau pathology (Xue and Streit, [@B286])\                                                       Not reported                                                                                                                                                                                                                                                                                                           Not reported                                                                                                                                             Hyper-reactive, dystrophic microglia associated with dense-core plaques and NFTs (McGeer et al., [@B169]; Streit et al., [@B249])\                                                                                                                                                     
                                                    Increased astrocytic activation in early DS, increases with age and correlates with amyloid deposition (Royston et al., [@B215])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Reactive astrocytes locate early to dense-core plaques, triggered by Aβ (Itagaki et al., [@B116]; Pike et al., [@B198]) Higher neuroinflammation in younger (\<80) compared to older patients with SAD, suggesting importance in early stages of disease (Hoozemans et al., [@B107])   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Down syndrome (AD-DS), familial AD due to APP duplications (Dup-APP), familial AD due to APP mutations (FAD), and sporadic Alzheimer disease (SAD) Abbreviations: BFCNs, basal forebrain cholinergic neurons; CAA, cerebral amyloid angiopathy; GABA, γ-Aminobutyric acid; ICH, intra-cranial hemorrhage; ID, intellectual disability; NFT, neurofibrillary tangles*.

However, a difficulty in analysing phenotypes is the considerable heterogeneity in clinical presentation within each *APP* genotype, even within families with the same mutation. For example, there is a wide variety of non-cognitive symptoms and behavioral changes across all four AD genotypes, including personality changes (Nelson et al., [@B185]; Ball et al., [@B8]), hallucinations (Sleegers et al., [@B247]; Basun et al., [@B9]; Guyant-Marechal et al., [@B92]), paranoia (Sleegers et al., [@B247]; Pilotto et al., [@B199]), and delusions (Burns et al., [@B26]), some of which are associated with cognitive decline (Adams and Oliver, [@B1]). Another important issue in diagnosing AD in AD-DS is that dementia is an additional cognitive deficit acquired on top of the baseline cognitive impairment found in people with DS: distinguishing between cognitive deficits due to intellectual disability, and decline at early stages of AD, is therefore an important challenge. However, diagnosis of dementia by experienced clinicians has been shown to be accurate in DS, and even more reliable than recent operational dementia criteria (Sheehan et al., [@B238]). Further, a few clinical features stand out in AD-DS---a striking example, albeit one of unknown relevance to AD, is seizure susceptibility in adulthood, which appears heightened by *APP* duplication, as both AD-DS (84%) and Dup-APP (57%) have significantly higher rates of seizures than SAD (10--20%). This may indicate specific pathways that are progressively disrupted by *APP* duplication, resulting in damaging electrical activity in the brain.

Dup-APP and FAD caused by *APP* mutations are relatively rare, and much information about these conditions remains to be gathered, for example, on synaptic dysfunction, oxidative stress and neuroinflammation. In contrast, AD-DS arises in a population with a well-defined genetic basis and a sizeable prevalence, which means it is of great value for investigating AD pathogenesis for everyone at risk of dementia.

Modeling DS, including AD-DS, in mice {#s3}
=====================================

Human chromosome 21 has synteny with the mouse genome, such that its ortholog genes are found in three blocks with conserved order and gene orientation on mouse chromosomes 10 (Mmu10), Mmu16, and Mmu17 (Hattori et al., [@B99]; Dierssen et al., [@B69]); the mouse *App* gene lies on Mmu16 (Figure [1](#F1){ref-type="fig"}). Mice with precisely-defined trisomies (or monosomies) have been generated, now usually by chromosome engineering (Brault et al., [@B24]; Tybulewicz and Fisher, [@B260]), to provide a set of models that are segmentally trisomic for regions orthologous to Hsa21 (Davisson et al., [@B58]; Sago et al., [@B223]; Olson et al., [@B188]; Li et al., [@B145]; Herault et al., [@B102]; Pereira et al., [@B196]; Yu et al., [@B290]; Liu et al., [@B146], [@B147]; Brault et al., [@B22]).

![**Human chromosome 21 (Hsa21), orthologous mouse chromosomes (Mmu), and key mouse models of Down syndrome**. Diagram representing Hsa21 and its alignment with syntenic regions on Mmus 16, 17, and 10. The orange circle represents the human centromere and mouse models are color-coded and aligned according to the chromosomal segment for which they are trisomic. Numbers in brackets represent the number of protein-coding Hsa21 orthologous genes within each region or mouse model, according to Ensembl release 79 and the breakpoints published in papers referenced here. The Tc1 mouse is the only model which carries Hsa21, though genomic rearrangements and deletions (indicated by breaks in the chromosome) mean the mouse is functionally trisomic for only \~75% of Hsa21 genes (Gribble et al., [@B88]). All other mouse models carry duplications of mouse orthologues. The Dp1(16)Yey;Dp1(17)Yey;Dp1(10)Yey (or Ts1Yey;Ts3Yey;Ts2Yey) mouse was generated by crossing together three partial trisomy models (Yu et al., [@B290]) and spans the entirety of the Hsa21-syntenic regions. The Ts65Dn mouse (Davisson et al., [@B58]) contains a freely segregating segment of Mmu16, however it is also trisomic for 43 extra protein-coding genes on the centromeric section of Mmu17 that are not relevant to DS (indicated by an asterisk (^\*^) and accompanying text box; Duchon et al., [@B72]; Reinholdt et al., [@B210]). The Ts1Cje mouse (Sago et al., [@B223]) also contains a monosomy of eight protein-coding genes on Mmu12, irrelevant to the DS phenotype (indicated by "\#" and accompanying text box. Gene numbers are based on Ensembl release 79, compared to the original seven monosomic genes detailed in Duchon et al., [@B72]). Other mice are Ts1Rhr or Dp1(16)Rhr mice (Olson et al., [@B188]); Ts1Yah mice (Pereira et al., [@B196]); Ts3Yah (previously published as Ts2Yah; Brault et al., [@B22]); and Ts4Yah mice (previously published as Ts3Yah mice; Herault et al., [@B102]). Other useful examples of mouse models include the Ts43H model (not shown) which is partially trisomic for Mmu17 including some genes with ortholog on Hsa21 (Vacík et al., [@B262]). The scale is in megabase pairs (Mb).](fnbeh-09-00268-g0001){#F1}

Generating many models with different partial trisomies creates a mapping panel in which individual phenotypes may be assessed in several strains, and so assigned to specific trisomic chromosomal region(s). As all DS phenotypes presumably arise from abnormal gene dosage, candidate genes that when present in three copies give rise to all or part of the phenotype, can be chosen from the trisomic critical region. Individual candidate genes can then be studied, for example, in overexpression or knockout models, to assess the effects of different copy numbers of the gene. Figure [1](#F1){ref-type="fig"} is an overview of DS mouse models and the chromosomal segments for which they are trisomic. Table [2](#T2){ref-type="table"} details the gene content for each DS mouse model shown, including protein-coding and non-protein-coding genes relevant to human trisomy 21.

###### 

**Trisomic region and triplicated gene content in Down syndrome mouse models shown in Figure [1](#F1){ref-type="fig"} compared with Hsa21 (Ensembl release 79)**.

                                                                                                                                             **Protein-coding genes**   **Non-protein-coding genes**   **Total genes**   **% Protein-coding genes from Hsa21**               
  ------------------------------------------------------------------------------------------------------ ----------------------------------- -------------------------- ------------------------------ ----------------- --------------------------------------- ----- ----- ----
  Tc1                                                                                                    B6;129S-Tc(Hsa21)1TybEmcf/J         --                         175                            --                Undetermined                            --    N/A   75
  Dp(16)1Yey                                                                                             B6.129S7-Dp(16Lipi-Zbtb21)1Yey/J    149                        112                            112               6                                       261   118   48
  Dp(17)1Yey                                                                                             B6;129S7-Dp(17Abcg1-Rrp1b)3Yey/J    19                         18                             6                 0                                       25    18    8
  Dp(10)1Yey                                                                                             B6;129S7-Dp(10Prmt2-Pdxk)2Yey/J     55                         39                             20                1                                       75    40    17
  Ts65Dn[^\*\*^](#TN2){ref-type="table-fn"}                                                              B6EiC3Sn a/A-Ts(1716)65Dn           133                        98                             71                3                                       204   101   42
  Ts1Cje[^\*\*\*^](#TN3){ref-type="table-fn"}                                                            B6.Cg-T(12;16)1Cje/CjeDnJ           76                         70                             51                1                                       127   71    30
  Ts1Rhr                                                                                                 B6.129S6-Dp(16Cbr1-Fam3b)1Rhr/J     32                         30                             20                0                                       52    30    13
  Dp(16)2Yey                                                                                             129-Dp(16Tiam1-Kcnj6)6Yey/J         53                         50                             37                1                                       90    51    22
  Dp(16)3Yey                                                                                             129-Dp(16Tiam1-Il10rb)8Yey/J        18                         16                             12                0                                       30    16    7
  Dp(16)4Yey                                                                                             129-Dp(16Ifnar1-Kcnj6)10Yey/J       35                         34                             24                1                                       59    35    15
  Ts1Yah                                                                                                 B6;129P2-Dp(17Abcg1-Cbs)1Yah/Orl    15                         14                             4                 0                                       19    14    6
  Ts3Yah (previously Ts2Yah)                                                                             B6;129P2-Dp(16Hspa13-App)2Yah/Orl   19                         15                             45                5                                       64    20    6
  Ts4Yah (previously Ts3Yah)                                                                             B6.Cg-Dp(10Prmt2-Cstb)3Yah/Orl      54                         38                             20                1                                       74    39    16
  **TRISOMIC/MONOSOMIC REGIONS AND GENE CONTENT IRRELEVANT TO Hsa21 AND ITS SYNTENIC REGIONS IN MICE**                                                                                                                                                                       
  Ts65Dn[^\*\*^](#TN2){ref-type="table-fn"}                                                              B6EiC3Sn a/A-Ts(1716)65Dn           43                         --                             36                --                                      79    --    
  Ts1Cje[^\*\*\*^](#TN3){ref-type="table-fn"}                                                            B6.Cg-T(12;16)1Cje/CjeDnJ           8                          --                             4                 --                                      12    --    

*Mouse genome informatics site that includes the official mouse strain names [www.informatics.jax.org](http://www.informatics.jax.org); the shaded line shows number of Hsa21 genes*.

indicates gene content of Ts65Dn and

*indicates gene content of Ts1Cje mice*.

The most complete mouse model to date, *Dp(10)1Yey/*+*;Dp(16)1Yey/*+*;Dp(17)1Yey/*+, is trisomic for all Hsa21 syntenic regions and was generated by crossing three DS mouse models, each carrying duplications of the respective Hsa21 orthologous regions on Mmu10, Mmu16 and Mmu17 (Li et al., [@B145]; Yu et al., [@B290],[@B289]; Figure [1](#F1){ref-type="fig"}). However, the vast majority of studies relating to AD-DS have been performed on the Ts65Dn mouse, as this has been an extremely important "standard model" of DS for many years, prior to the development of newer strains by chromosome engineering (Davisson et al., [@B58]; Reeves et al., [@B209]; Table [2](#T2){ref-type="table"}). The Ts65Dn mouse carries a Robertsonian translocation resulting in trisomy of \~42% of the protein-coding genes orthologous to Hsa21, but it also has 79 additional genes (including long non-coding sequences) from Mmu17 that are outside the Hsa21 region of synteny, and these need to be taken into account when analysing phenotypes (Duchon et al., [@B72]; Reinholdt et al., [@B210]). These extra triplicated genes that do not relate to DS happen to include non-Hsa21 genes, such as *SYNJ2* and *TIAM2* that have Hsa21/Mmu16 paralogues (*SYNJ1, TIAM1*), which may complicate phenotype-genotype correlations (Duchon et al., [@B72]). Other triplicated genes in Ts65Dn irrelevant to DS include several genes encoding dynein light chains that may influence endosomal trafficking, and so potentially affect neuronal phenotypes (Hartley et al., [@B97]).

A different type of mouse model of DS is the "humanized" transchromosomic "Tc1" mouse that carries a freely-segregating Hsa21 (O\'Doherty et al., [@B187]), which is functionally trisomic for \~75% of Hsa21 protein-coding genes (Gribble et al., [@B88]). However, this extra chromosome is rearranged, and lost stochastically at different rates in different mouse tissues---thus, Tc1 mice are mosaic for the human chromosome. With respect to AD research, the *APP* gene is not functionally trisomic in Tc1 mice because of a rearrangement that has occurred by chance, so this animal expresses just the two endogenous copies of mouse *App* (Sheppard et al., [@B240]).

While many DS mouse models have been published, there is no single complete model, and the usefulness of these strains lies in their comparative and complementary use in studying genotype-phenotype relationships, including AD-related phenotypes (Table [3](#T3){ref-type="table"}). These studies enable us to map critical dosage-sensitive genes because each locus is likely expressed at trisomic levels, mimicking human DS transcription. We can also study the interactions of Hsa21 dosage-sensitive genes with the rest of the genome (Hsa21 and non-Hsa21), as well as effects exerted by aneuploidy *per se*.

###### 

**Examples of AD phenotypes studied in DS mouse models, and related findings in *APP* transgenic strains described in Table [4](#T4){ref-type="table"}**.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Phenotype**                                   **DS models**                                                                                                                                                                                                                                                                               ***APP* transgenic models**                                                                                                                                                                                                                                                                                 
  ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cognitive deficits                              Learning and memory deficits widely demonstrated, mostly in young mice (Das and Reeves, [@B57])\                                                                                                                                                                                            Working memory, episodic memory, executive function, and attention deficits in *APP* transgenic mice from young ages (3--5 months; Webster et al., [@B273])\                                                                                                                                                
                                                  Differentiating between early cognitive impairment and neurodegeneration in old age is a challenge (Ruparelia et al., [@B216]).\                                                                                                                                                            Memory impairments linked to neurotoxicity as a result of Aβ oligomers (Lesné et al., [@B142]) or insoluble Aβ deposits (Westerman et al., [@B277])\                                                                                                                                                        
                                                  One study suggests learning deficits in Ts65Dn worsen with age, but due to lack of motivation or motor impairment rather than neurodegeneration (Sanders et al., [@B229])                                                                                                                   Behavioral deficits deteriorate with age in some *APP* transgenic mice (Hsiao et al., [@B109]; Van Dam et al., [@B263])                                                                                                                                                                                     

  Long-term potentiation (LTP)                    Hippocampal LTP deficits reported in all models trisomic for Mmu16 regions syntenic to Hsa21, apart from Ts2Yah for which no LTP data is available (Das and Reeves, [@B57])\                                                                                                                LTP studies have produced often contradictory measurements within the same mouse models (Pozueta et al., [@B204])\                                                                                                                                                                                          
                                                  LTP increased in Dp1(17)Yey and unaltered in Dp1(10)Yey (Yu et al., [@B289])\                                                                                                                                                                                                               Aberrant neuronal activity is a prominent feature; restoring inhibitory synaptic activity may rescue network hypersynchrony, memory deficits and early mortality (Sanchez et al., [@B227]; Verret et al., [@B266]; Stargardt et al., [@B248])                                                               
                                                  LTP deficits observed in Tc1 suggest compromised entorhinal cortex input into the dentate gyrus, contributing to impaired CA3 and CA1 function (Witton et al., [@B282])                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Aβ accumulation and deposition                  APP protein and mRNA expression                                                                                                                                                                                                                                                             In Ts65Dn, APP protein increases to trisomic levels from 6 months in the striatum (Hunter et al., [@B112]), and from 10 months in cortex and hippocampus (Seo and Isacson, [@B234]; Contestabile et al., [@B47])\                                                                                           *APP* transgenic mice generally overexpress human *APP* with FAD mutations at levels at least 5x endogenous mouse *App*. *APP* transgene transcription is directed by artificial promoters (Table [4](#T4){ref-type="table"}) allowing expression in the central nervous system, usually from embryonic or early postnatal age (Crews et al., [@B54]; Balducci and Forloni, [@B7]; Hall and Roberson, [@B94])
                                                                                                                                                                                                                                                                                                                                              APP mRNA in Ts65Dn remains similar to disomic levels at 5 months but increases at 12 months (Choi et al., [@B44])                                                                                                                                                                                           

                                                  APP metabolism                                                                                                                                                                                                                                                                              In Ts65Dn, total APP CTF levels increased in hippocampus, enriched in synaptosomes and early endosomes from 6 months (Salehi et al., [@B226]; Lockrow et al., [@B152])\                                                                                                                                     In line with the overexpression of *APP*, Aβ levels are generally overexpressed, with some models expressing FAD mutations driving an increase in Aβ42/40 ratios (Crews et al., [@B54])
                                                                                                                                                                                                                                                                                                                                              In Ts65Dn no difference in Aβ42/40 ratios, low levels of larger (\~115 kDa) SDS-stable Aβ oligomers (Salehi et al., [@B226]; Choi et al., [@B44]; Peng et al., [@B195])                                                                                                                                     

  Tau                                             Neurofibrillary pathology                                                                                                                                                                                                                                                                   In aged Ts65Dn mice increased tau and reelin detected in granules in hippocampus and olfactory bulb (Kern et al., [@B125]) No tau neurofibrillary tangles detectable in Tc1 and Ts1Cje brains (O\'Doherty et al., [@B187]; Shukkur et al., [@B244]; Sheppard et al., [@B240])                               *APP* transgenic mice fail to produce neurofibrillary tangles without additional mutations introduced in presenilin or tau (Kokjohn and Roher, [@B128])

                                                  Tau hyper-phosphorylation                                                                                                                                                                                                                                                                   In Ts65Dn, Ts1Cje and Tc1, increased tau phosphorylation in hippocampus and cortex at various phosphorylation sites (Shukkur et al., [@B244]; Liu et al., [@B148]; Sheppard et al., [@B240])\                                                                                                               Hyperphosphorylation of tau and its regulation have primarily been studied in *APP* transgenic mice with additional mutations in presenilin and/or tau\
                                                                                                                                                                                                                                                                                                                                              In Tc1 this was detected in old (20 months) but not young (2 months) mice (Sheppard et al., [@B240])\                                                                                                                                                                                                       Hyperphosphorylated tau is detectable in some *APP* transgenic mouse models (Kokjohn and Roher, [@B128]; Crews et al., [@B54])
                                                                                                                                                                                                                                                                                                                                              Unphosphorylated tau decreased in Ts1Cje mice (Shukkur et al., [@B244])                                                                                                                                                                                                                                     

                                                  Regulation of tau phosphorylation                                                                                                                                                                                                                                                           Increased phosphorylation of GSK-3β in Tc1 and Ts1Cje (Shukkur et al., [@B244]; Sheppard et al., [@B240]). Increased phosphorylation of AKT in Tc1 and Ts65Dn (Siarey et al., [@B245]; Sheppard et al., [@B240])\                                                                                           
                                                                                                                                                                                                                                                                                                                                              CDK5 expression upregulated in Ts65Dn but not in Tc1 (Pollonini et al., [@B200]; Sheppard et al., [@B240]). No difference in CDK5 activators p25/p35 levels detected in both Ts1Cje and Tc1 (Shukkur et al., [@B244]; Sheppard et al., [@B240])                                                             

  Neuronal loss and dysfunction                   Loss and dysfunction of Basal Forebrain Cholinergic Neurons (BFCNs)                                                                                                                                                                                                                         Reduced BFCN numbers and cell size in Ts65Dn mice from 12 months (Cooper et al., [@B48]; Salehi et al., [@B226])\                                                                                                                                                                                           Loss of BFCNs observed in APP23 and APP(V717I; Choi et al., [@B45]). No loss of BFCNs observed in APP23 (Boncristiano et al., [@B15]) and Tg2576 (Apelt et al., [@B3])\
                                                                                                                                                                                                                                                                                                                                              ChAT activity increased in 10-month but no different from control in 19-month Ts65Dn (Contestabile et al., [@B47])\                                                                                                                                                                                         Decreased ChAT and AChE activity in basal forebrain nuclei of APP23 (Van Dam et al., [@B264])
                                                                                                                                                                                                                                                                                                                                              Distribution of cholinergic neurons in dentate gyrus altered in Ts65Dn (Cooper et al., [@B48]; Salehi et al., [@B226])\                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                              All above alterations not observed in Ts1Cje and Ts65Dn:App^+∕+∕−^ mice, both of which are disomic for *App* (Salehi et al., [@B226])                                                                                                                                                                       

                                                  Loss and dysfunction of noradrenergic neurons                                                                                                                                                                                                                                               Degenerative morphology and loss of noradrenergic neurons in rostral LC in Ts65Dn at 12 months but not 4 months (Lockrow et al., [@B151]; Fortress et al., [@B77])                                                                                                                                          Noradrenaline levels declined with aging in TgCRND8 hippocampus (Francis et al., [@B78]). No overt cell loss in LC in old APP23 and PDAPP mice, although neurons decreased in size in PDAPP (Szot et al., [@B254]; Francis et al., [@B78])

  **OTHER FEATURES POTENTIALLY RELEVANT TO AD**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Epilepsy                                        5--10x increased rates of audiogenic seizures and seizure-related death in 21-day old Ts65Dn mice, attenuated by mGluR5 antagonists (Westmark et al., [@B278])                                                                                                                              Epileptiform activity and spontaneous non-convulsive seizures frequently observed in *APP* transgenic mice, from young ages (Born, [@B18]). Whether this is caused by overproduction of Aβ (Palop, [@B189]) or is an artifact of *APP* overexpression during development (Born et al., [@B17]) is unclear   

  Synaptic loss and dysfunction                   Synaptic and dendritic abnormalities                                                                                                                                                                                                                                                        In Ts65Dn, increased average synapse size with no change in synaptic number or density (Hernández-González et al., [@B103])\                                                                                                                                                                                Loss and alterations in dendritic spines and synapses are early features of neuronal pathology in *APP* transgenic mice models, before onset of plaque deposition and cognitive deficits. Synaptic deficits correlate well with soluble Aβ (Pozueta et al., [@B204]) Reduced density of mushroom-type spines of CA1 hippocampal region in two *APP* transgenic mouse models (Perez-Cruz et al., [@B197])
                                                                                                                                                                                                                                                                                                                                              In Ts65Dn, dendritic spines are enlarged, less dense, and redistributed on principal neurons; arborizations are poorly developed. Similar but less severe observations in Ts1Cje (Dierssen et al., [@B68]; Belichenko et al., [@B12])\                                                                      
                                                                                                                                                                                                                                                                                                                                              In Tc1, reduced synaptic size, complexity and density observed in hippocampus (Witton et al., [@B282]); decreased dendritic mushroom spines (associated with memory) at 3 months and increase in stubby spines (Haas et al., [@B93])\                                                                       
                                                                                                                                                                                                                                                                                                                                              Ts1Rhr fewer thin spines (associated with learning) at 3 weeks of age (Haas et al., [@B93])                                                                                                                                                                                                                 

  Oxidative stress and proteostasis               Oxidative stress markers increased in young and old Ts65Dn mice (Lockrow et al., [@B152]; Shichiri et al., [@B243]; Di Domenico et al., [@B66])\                                                                                                                                            Oxidative stress increased and precedes Aβ deposition in *APP* transgenic mice. Increased Aβ levels lead to mitochondrial impairments (Eckert et al., [@B73]; Ye et al., [@B288]; Meraz-Ríos et al., [@B171])                                                                                               
                                                  Impaired mitochondrial function and increased ROS production in Ts1Cje cortical astrocyte and hippocampal neuronal cultures (Shukkur et al., [@B244])                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Endosomal dysfunction                           Enlarged EEs in BFCNs and expression of EE proteins detected from 6 months in Ts65Dn, increasing in number with age (Cataldo et al., [@B35]; Salehi et al., [@B226]) EEs not enlarged in Ts1Cje and Ts65Dn-App^+∕+∕−^ mice, both of which are disomic for *App* (Cataldo et al., [@B35])\   No enlargement of EEs observed in APP22 and APP23 mice (Cataldo et al., [@B35]). Enlarged EEs found in APP23 (Choi et al., [@B45])\                                                                                                                                                                         
                                                  Axonal transport disruption selectively impaired for endosomal cargo in Ts65Dn mice (Salehi et al., [@B226])                                                                                                                                                                                Aβ42 accumulates in endosomal compartments in Tg2576 mice before plaque deposition, and increases with age (Takahashi et al., [@B255])                                                                                                                                                                      

  Neuroinflammation and glial phenotypes          Increased astrocytic protein expression and metabolic activity in old Ts65Dn mice (Holtzman et al., [@B105]; Contestabile et al., [@B47])\                                                                                                                                                  Astrocytic changes in morphology and increased calcium signaling in *APP* transgenic mice (Takano et al., [@B256]; Beauquis et al., [@B11]; Rodríguez-Arellano et al., [@B212])\                                                                                                                            
                                                  Increased microglial activation in basal forebrain and hippocampus of old Ts65Dn mice (Hunter et al., [@B111]; Lockrow et al., [@B150])                                                                                                                                                     Impairments in microglia phagocytosis and increased microglia proliferation around plaques in APP23 and Tg2576 (Frautschy et al., [@B80]; Krabbe et al., [@B131])                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Abbreviations: AChE, acetylcholinesterase; AKT, protein kinase B; BFCN, basal forebrain cholinergic neuron; CA1, Cornu Ammonis area 1; CDK5, cyclin-dependent kinase 5; ChAT, choline acetyltransferase; CTF, C-terminal fragment; EE, early endosome; GSK-3β, glycogen synthase kinase 3β; LC, locus coeruleus; LTP, long-term potentiation; mGluR5, metabotropic glutamate receptor 5; ROS, reactive oxygen species; SDS, sodium-dodecyl sulfate*.

Modeling amyloid deposition in mice {#s4}
===================================

In contrast to the segmental duplication of tens of endogenous wildtype genes in DS mouse strains, AD models are primarily transgenic lines that overexpress one or more of the human mutant genes that cause FAD. These transgenes usually insert at random sites in the genome and may be driven by artificial promoters (see examples in Table [4](#T4){ref-type="table"}), which vary in terms of their spatial and temporal expression patterns, and result in expression at often 5--10 fold compared to endogenous mouse orthologue (Balducci and Forloni, [@B7]; Hall and Roberson, [@B94]). Overexpressing wildtype human *APP* or mouse *App* does not result in amyloid deposition (Elder et al., [@B74]); hence the need to use known AD-causative mutant sequences in transgenic mice.

###### 

**Human *APP* overexpressing transgenic mice referred to in this review (information obtained from Alzforum.org)**.

  **Mouse**    **Mutation**                                   **Promoter**            **Genetic Background**                                                           **References**
  ------------ ---------------------------------------------- ----------------------- -------------------------------------------------------------------------------- -----------------------------------
  APP22        APP751 KM670/671NL (Swedish), V717I (London)   Human THY1              C57BL/6                                                                          Sturchler-Pierrat et al., [@B250]
  APP23        APP751 KM670/671NL (Swedish)                   Mouse Thy1              C57BL/6                                                                          Sturchler-Pierrat et al., [@B250]
  APP(V717I)   APP695 V717I (London)                          Mouse Thy1              Originally generated on FVB/N background; available at reMYND as C57BL/6xFVB/N   Moechars et al., [@B173]
  Tg2576       APP695 KM670/671NL (Swedish)                   Hamster prion protein   C57BL/6;SJL mixed background                                                     Hsiao et al., [@B109]
  TgCRND8      APP KM670/671NL (Swedish), V717F (Indiana)     Hamster prion protein   C3H/He-C57BL/6 mixed background                                                  Chishti et al., [@B43]
  PDAPP        APP V717F (Indiana)                            Human PDGF              C57BL/6 x DBA2                                                                   Games et al., [@B82]

In general, while mutant *APP* transgenic mice develop robust amyloid deposition, synaptotoxic features and memory impairments, none of them reproduces tau-containing neurofibrillary tangles, the hallmark pathology of AD which most closely correlates with dementia (Hall and Roberson, [@B94]). The combined overexpression of mutant *APP* and mutant human tau is required to reproduce both amyloid and tau pathology, although these tau mutations in humans do not alone cause AD but another form of neurodegeneration, frontotemporal dementia. Mutant *APP* transgenics may be best considered models of APP/Aβ pathology (amyloid deposition) rather than full AD.

Studying AD-DS phenotypes in mice {#s5}
=================================

In Table [3](#T3){ref-type="table"}, we summarize examples of findings that may be informative for AD-DS from different DS (mainly Ts65Dn) mice and examples of AD models (Table [4](#T4){ref-type="table"}). With respect to AD, a wide range of mutant *APP* transgenic strains are available in the literature, so we have chosen a few well-known examples \[APP22, APP23, APP (V717I), PDAPP, Tg2576, TgCRND8\] to illustrate some potential phenotypes of interest. We note that the expression of wildtype mouse APP, and wildtype or mutant human APP protein in these different models can influence amyloid pathology (Kokjohn and Roher, [@B128]). For example, because of amino acid differences between the two species, mouse APP may be processed with little BACE1 cleavage and so may yield three times less Aβ than wildtype human APP (De Strooper et al., [@B60]). In addition, the genetic background of AD mouse strains affects a range of APP/Aβ phenotypes, including plaque deposition, APP metabolism, survival, and seizure rates (Carlson et al., [@B30]; Lehman et al., [@B141]; Krezowski et al., [@B132]; Lassalle et al., [@B139]; Rustay et al., [@B217]; Jackson et al., [@B118]). Similarly, phenotypes observed in DS mice may be influenced by genetic background (O\'Doherty et al., [@B187]; Galante et al., [@B81]; Costa et al., [@B52]; Deitz and Roper, [@B61]; Haydar and Reeves, [@B100]). We consider only *APP* transgenic models of AD, as the other genes used in such models (*PSEN1, PSEN2*, and *MAPT*) are not encoded on Hsa21, and therefore are not directly relevant to AD-DS.

In studying mouse phenotypes to understand AD-DS, we are presented with two key issues. Firstly, we need to test longitudinally DS models to look for changes in older mice that are not apparent early on, and so may indicate aging or neurodegenerative processes rather than neurodevelopmental deficits. Secondly, we need to separate normal aging processes in DS from those connected specifically to AD-DS. The thoughtful use of the increasing range of different mouse models is enabling us to dissect these issues to further our understanding of AD-DS.

A study that has addressed both (1) neurodegenerative vs. neurodevelopmental and (2) normal aging vs. AD phenotypes has been performed in the Ts65Dn mouse. This study concerned the neurodegenerative phenotype loss of basal forebrain cholinergic neurons (BFCNs), and was carried out through an experimental design involving optimal crossing of different mouse models and assessment of the genetically-distinct progeny (Salehi et al., [@B226]). Firstly, Salehi and colleagues quantified the known loss of BFCNs in Ts65Dn mice, and showed this loss to be progressive, thus an aging or an AD-related phenotype in this DS mouse model. The authors then compared BFCN loss in Ts65Dn and Ts1Cje DS mouse models (Figure [1](#F1){ref-type="fig"}), and were able to map a dosage-sensitive critical region that had to contain a candidate gene for this phenotype: Ts65Dn mice lose BFCNs but Ts1Cje mice turned out to have no loss compared to wildtype mice. Therefore, the dosage-sensitive gene(s), that when present in three copies is responsible for BFCN loss, must map within the region of trisomy present in Ts65Dn but not in Ts1Cje. A key candidate in this region was the *App* gene. By crossing Ts65Dn mice to heterozygous *App* knockout mice, the authors generated cohorts of progeny that carried the trisomic region with either two or three copies of wildtype *App*. Assessing BFCN loss in these cohorts led to the conclusion that the phenotype arises mainly from having three copies of *App* and, further, that it is associated with impairments in nerve growth factor retrograde transport, linked to early endosomes, which are enlarged (Salehi et al., [@B226]).

Given the role of *APP* triplication in this phenotype, there is likely a strong link to AD and AD-DS. In people with early AD pathology or mild cognitive impairment, neurofibrillary pathology has been detected in BFCNs (Mesulam et al., [@B172]; Grudzien et al., [@B91]), while their loss has been observed in patients with SAD (and other neurodegenerative disorders; Zarow et al., [@B291]). Interestingly, enlarged early endosomes have been detected in cortical tissues from cognitively intact individuals with mild AD pathology, and in young individuals with DS (under 12 years old), suggesting that endosome enlargement is an early feature in AD pathogenesis (Cataldo et al., [@B36]).

DS models in the study of candidate genes influencing AD {#s6}
========================================================

As illustrated in Table [1](#T1){ref-type="table"}, while people with DS have three copies of *APP* and develop early AD neuropathology, their clinical presentation is variable, suggesting that other genetic and environmental factors influence pathogenesis. In addition to *APP*, many genes on Hsa21 have been studied in the context of neurodegeneration and/or AD, and it is conceivable that a three-copy dose of any of these genes could contribute to disease and dysfunction.

Single gene overexpressing transgenics do not model DS, or AD-DS, but may provide some insights if carefully considered. For example, seizures and neuronal network abnormalities remain challenging areas to investigate but important phenotypes to be explored in DS, AD-DS, and *APP* overexpression models of AD (i.e., which are single gene transgenic models). In SAD, seizures have been associated with early cognitive decline (Vossel et al., [@B269]), while the incidence of seizures in AD-DS is high and is associated with increased risk of dementia (for example, McCarron et al., [@B166]). To date, seizure phenotypes and epileptiform activity have been characterized across numerous *APP* transgenic mice (Born, [@B18]), but it is unclear whether these phenotypes are primarily driven by amyloid overproduction (Mucke and Selkoe, [@B178]) or are an effect of unphysiological *APP* overexpression during development (Born et al., [@B17]). Antiepileptic drugs, such as levetiracetam, which improve seizures in DS (Sangani et al., [@B230]) and in AD (Cumbo and Ligori, [@B55]), also ameliorate synaptic and memory dysfunctions in APP transgenic mice by suppressing neuronal network dysfunction (Sanchez et al., [@B228]; Devi and Ohno, [@B65]).

So, while single gene transgenic models do not model human trisomy 21 or AD because they usually express the gene by many-fold, from ectopic promoters, they offer insights into some of the functional consequences of overexpression, albeit at non-trisomic levels. Table [5](#T5){ref-type="table"} presents a list of Hsa21 gene candidates, in chromosomal order, that have been investigated for overexpression-related phenotypes linked with AD across different mouse, fruitfly, and cellular models. We also compare, where data are available, how related changes in these genes have been explored in humans with AD and/or DS. Making optimal use of mouse genetics, some of the single-gene-overexpressing mouse transgenics have been crossed with AD models, to look for changes in phenotypes that may be informative. For example, crossing an *S100*β overexpression model with the Tg2576 *APP* transgenic mouse generates double mutant progeny with exacerbated cerebral amyloidosis and reactive gliosis. This suggests that increased expression of *S100*β could contribute to AD pathogenesis possibly by promoting amyloidogenic APP processing (Mori et al., [@B177]).

###### 

**Single gene overexpression models from Hsa21, with relevance to AD phenotypes. Genes are listed in order from centromere to Hsa21q telomere**.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Hsa21 gene**   **Phenotypes studied in models**                                                                                                                                                                                                                                  **Phenotypes studied in humans**
  ---------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  *APP*            Please refer to Table [3](#T3){ref-type="table"}.                                                                                                                                                                                                                 Please refer to Table [1](#T1){ref-type="table"}

  *SOD1*           *SOD1* overexpression protects against APP-induced lethality in transgenic mice (Carlson et al., [@B30])                                                                                                                                                          SOD1 activity positively correlates with levels of memory functioning in DS adults (Zis et al., [@B296])

  *ITSN1*          Overexpression of *ITSN1* homolog *nla* in combination with *SYNJ1* and *RCAN1* homologs causes impaired vesicle recycling in *Drosophila* (Chang and Min, [@B38])                                                                                                ITSN1 protein (Hunter et al., [@B113]) and mRNA (Pucharcos et al., [@B207]) elevated in DS\
                                                                                                                                                                                                                                                                                     *ITSN1* highly expressed in AD brain (Blalock et al., [@B14]; Wilmot et al., [@B279])

  *SYNJ1*          Mice overexpressing *SYNJ1* have deficits in synaptic transmission (Voronov et al., [@B268])\                                                                                                                                                                     SYNJ1 levels higher in DS brain tissue compared to controls, and elevated in AD-DS cases (Martin et al., [@B164])
                   *SYNJ1* transgenic mice display enlarged endosomes (Cossec et al., [@B51])                                                                                                                                                                                        

  *OLIG2*          Neural progenitors from *Olig2*-overexpressing mice exhibit impairments in neural progenitor proliferation (Lu et al., [@B155])                                                                                                                                   SNPs in *OLIG2* associated with psychotic symptoms in AD (Sims et al., [@B246])

  *RCAN1*          *RCAN1* overexpression in a mouse model causes abnormal tau phosphorylation (Wegiel et al., [@B275])\                                                                                                                                                             *RCAN1* chronically elevated in AD and DS (Ermak et al., [@B75])
                   In cell models, *RCAN1* overexpression leads to deficits in synaptic transmission (Martin et al., [@B163]) and promotes neuronal apoptosis (Sun et al., [@B252], [@B253])                                                                                         

  *DYRK1A*         *DYRK1A* overexpression linked to tau hyperphosphorylation and increased Aβ production in transgenic mice (Ryoo et al., [@B220], [@B219]) and cellular models (Park et al., [@B190]; Coutadeur et al., [@B53])\                                                   DYRK1A increased in the brains of patients with AD (Kimura et al., [@B127]) and DS (Ryoo et al., [@B219])\
                   *Dyrk1a* overexpression causes phosphorylation of PS1, increasing γ-secretase activity in cells and stabilizing γ-secretase complex in mice (Ryu et al., [@B221])\                                                                                                DYRK1A expression in DS brain correlates with 3-repeat tau levels (Shi et al., [@B241]; Wegiel et al., [@B275])\
                   Mouse *Dyrk1a* overexpression in TgDyrk1A mice results in a significant reduction of *Rest* mRNA (Canzonetta et al., [@B29])                                                                                                                                      Plasma DYRK1A positively correlates with cerebrospinal fluid tau and phospho-tau in AD patients (Janel et al., [@B119])\
                                                                                                                                                                                                                                                                                     Co-localization of DYRK1A with NFTs greater in AD-DS than SAD (Wegiel et al., [@B274])\
                                                                                                                                                                                                                                                                                     REST levels correlate with cognitive preservation and longevity in aging and are downregulated in AD (Lu et al., [@B156])

  *DSCAM*          Trisomy of *Dscam* in *Drosophila* results in synaptic targeting errors (Cvetkovska et al., [@B56])                                                                                                                                                               DSCAM overexpressed in a DS patient, and DSCAM immunoreactivity associated with Aβ plaques in demented DS patients (Saito et al., [@B225])

  *ETS2*           *Ets2* transgenic mice and fibroblasts overexpressing ETS2 have elevated APP, presenilin1 protein and increased Aβ production (Wolvetang et al., [@B284])\                                                                                                        ETS2 immunoreactivity associated with intracellular Aβ and hyperphosphorylated tau in both AD-DS and sporadic AD brain tissue (Helguera et al., [@B101])
                   *Ets2* overexpression causes apoptosis via caspase 3 activation in primary neuronal cultures (Wolvetang et al., [@B283]) and in DS cortical neurons (Helguera et al., [@B101])                                                                                    

  *BACE2*          *BACE2* overexpression *in vitro* reduces Aβ levels (Sun et al., [@B251]) In a mouse model, overexpression of *BACE2* has no effect on Aβ production (Azkona et al., [@B4],[@B5])                                                                                 *BACE2* polymorphisms may predict age of onset of dementia in DS (Myllykangas et al., [@B182]; Mok et al., [@B174])

                                                                                                                                                                                                                                                                                     

  *ABCG1*          *ABCG1* overexpression stimulates cholesterol efflux *in vitro* (Kim et al., [@B126]; Tansley et al., [@B257]) and either reduces (Kim et al., [@B126]) or increases Aβ production (Tansley et al., [@B257]), the latter through an increase in APP processing\   *ABCG1* gene upregulated in patients with DS (Tansley et al., [@B257]; Kong et al., [@B129])\
                   *ABCG1* overexpression in a mouse model has no effect on reference or working memory or synaptic plasticity (Parkinson et al., [@B192]), nor alters Aβ, APOE nor cholesterol efflux *in vivo* (Burgess et al., [@B25])                                            *ABCG1* gene expression unaltered in AD (Tansley et al., [@B257])

  *CSTB*           *Cstb* overexpression in a mouse model does not induce epileptic activity or a myoclonic seizure phenotype (Brault et al., [@B23])                                                                                                                                CSTB protein unaltered in DS fetal cerebral cortex (Cheon et al., [@B40]).

  *SUMO3*          *SUMO3* overexpression in cell culture systems shown to both increase (Dorval et al., [@B70]) and reduce (Zhang and Sarge, [@B294]) Aβ levels\                                                                                                                    High molecular weight SUMO3 conjugates decreased in AD brain tissue (Lee et al., [@B140])
                   *SUMO3* overexpression modulates APP processing, increasing the CTF/APP ratio *in vitro* (Dorval et al., [@B70])                                                                                                                                                  

  *S100β*          S100β application results in tau hyperphosphorylation in cultured neural stem cells (Esposito et al., [@B76])\                                                                                                                                                    *S100β* upregulated in DS and AD (Griffin et al., [@B89]; Sheng et al., [@B239])\
                   *S100β* overexpression increases neuronal death and reduces neuronal production in DS stem cells (Lu et al., [@B154])\                                                                                                                                            *S100β* overexpression positively correlates with age in DS patients (Royston et al., [@B215])
                   *S100β* overexpression in Tg2576 AD mice increases Aβ deposition and BACE1 activity (Mori et al., [@B177])\                                                                                                                                                       
                   Mice overexpressing *S100β* show accelerated signs of aging (Shapiro and Whitaker-Azmitia, [@B237]) neuropathology (Shapiro et al., [@B236]) and behavioral deficits (Borella et al., [@B16])                                                                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*SOD1, superoxide dismutase1; ITSN1, intersectin 1; SYNJ1, synaptojanin 1; OLIG2, oligodendrocyte transcription factor 2; RCAN1, regulator of calcineurin 1; DYRK1A, Dual specificity tyrosine-phosphorylation-regulated kinase 1A; DSCAM, Down syndrome cell adhesion molecule; ETS2, V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 2; BACE2, beta-site APP cleaving enzyme 2; ABCG1, ATP-binding cassette sub-family G member 1; CSTB, cystatin B; SUMO3, small ubiquitin-like modifier 3; S100β, S100 calcium binding protein β; REST, repressor element-1 silencing transcription factor*.

Other key Hsa21 gene candidates *DYRK1A* and *RCAN1* have been linked to AD pathogenesis through their effects on tau. The toxic neurofibrillary tangles (NFTs) that accumulate in AD are formed of hyperphosphorylated tau protein. Overexpression of *DYRK1A* in transgenic mice resulted in tau hyperphosphorylation (Ryoo et al., [@B220], [@B219]), and DYRK1A has been shown to co-localize with NFTs more frequently in AD-DS brain compared to SAD (Wegiel et al., [@B274]). Similarly, overexpression of *RCAN1* in a mouse model resulted in abnormal tau hyperphosphorylation (Wegiel et al., [@B275]). This suggests that the increased expression of *DYRK1A* and *RCAN1* in DS could promote the formation of NFTs, a hallmark feature of AD pathology.

Triplication of Hsa21 genes in DS does not necessarily lead to a 1.5-fold increase (compared to euploid individuals) in their RNA or protein expression. For example, a study in DS fetal cortical tissue revealed multiple Hsa21 proteins in fact expressed at similar or lower levels than in disomic controls (Cheon et al., [@B39],[@B40],[@B41],[@B42]). Assessments at transcriptomic and proteomic levels, together with meta-analysis across these studies, provide useful resources for understanding patterns of alteration in gene expression (for example, see Vilardell et al., [@B267]). As a few of the studies in Table [5](#T5){ref-type="table"} have demonstrated, it is important to verify the effect of trisomy on candidate gene expression, in relevant tissues and contexts, before further characterization of any potential downstream effects of trisomy.

Prospects for research {#s7}
======================

Individuals with DS manifest the most common genetic form of AD, and this undoubtedly largely arises from expressing three copies of *APP* (Ness et al., [@B186]; Hartley et al., [@B97]). Therefore, studying and modeling this population will assist in understanding the contribution of APP to AD pathogenesis, and evaluating the amyloid cascade hypothesis. However, the variation in clinical presentation of AD-DS shows that many other genetic and environmental factors contribute, almost certainly including protective factors. The thoughtful use of models will thus provide insight into these factors.

To study mouse models of AD-DS, it is critical to dissect neurodevelopmental from neurodegenerative effects (Bothwell and Giniger, [@B19]; Contestabile et al., [@B46]). To be of interest for AD-DS, such phenotypes should differ from normal aging in the mouse strain of interest, although this can be difficult to determine, particularly as DS has been characterized as a syndrome of accelerated aging in both clinical (Lott, [@B153]; Zigman, [@B295]) and epigenetic terms (Horvath et al., [@B108]), and because aging remains the clearest non-genetic risk factor for all forms of AD (Fratiglioni, [@B79]; Bush and Beail, [@B27]). The longitudinal study of cognitive decline in DS mice poses similar challenges to those in people with DS, and tests need to distinguish between dysfunction due to dementia, as opposed to aging or baseline learning deficits. For example, variations of a learning procedure involving incremental repeated acquisition tasks suggest that declining performances by Ts65Dn mice with age may be due to motor impairments and/or decreased motivation, rather than neurodegenerative-related effects (Sanders et al., [@B229]). To improve behavioral testing in mouse models of AD-DS, a potential avenue to explore capitalizes on the association of dementia with deficits in episodic memory. The development of tests based on, for example, visuo-spatial data, should therefore highlight age-dependent, dementia-related deficits in mouse models, because they rely on the encoding and binding of information spontaneously, and do not challenge other cognitive domains (Iordanova et al., [@B115]).

As well as the hypothesis-driven study of AD-DS phenotypes, one of the greatest strengths of working with mouse models is our ability to undertake unbiased hypothesis-generating research, by mapping phenotypes to genomic critical regions using the range of strains now available. These include chromosome-engineered panels of partially trisomic mice (Figure [1](#F1){ref-type="fig"}) as well as single gene knockout animals, such as the *App*^+∕−^ heterozygous mice, which may be crossed to partially trisomic strains, to generate progeny with altered single gene copy numbers on different trisomic region backgrounds. The cohorts of progeny from these crosses provide ideal groups for testing the contributions of single Hsa21 genes to AD-DS.

Mouse genome engineering continues to offer new models and approaches for teasing apart AD-DS relevant phenotypes, and new strains are being published regularly to help refine experimental strategies. For example, the recent genomically humanized NLF mouse (Saito et al., [@B224]), which has human amino acid residues at key sites within APP that affect its processing, may yield new insights into the biology of both AD and AD-DS, partly through expressing mutant *APP* at physiological levels. The strategic breeding of new *APP* models with DS segmental trisomies will contribute to determining which phenotypes are downstream of an amyloid cascade. Furthermore, independent study of partial trisomies without three copies of *App* may help tease out effects of other factors, for example oxidative stress, cholesterol metabolism or immune system dysfunction, in the development of dementia (Wiseman et al., [@B280]).

DS mouse models also give us the flexibility to investigate the effects of potentially dosage-sensitive non-coding regions. For example, microRNAs (miRs)---short (20--23 nucleotide) RNAs that downregulate the transcription of target genes---have increasingly been investigated in AD pathogenesis due to their differential regulation in molecular pathways associated with AD (Veerappan et al., [@B265]). Hsa21 encodes 29 miRs (MirBase release 21, Griffiths-Jones, [@B90]), and their potential overexpression in trisomy may contribute to genetic dysregulation relevant to AD-DS. Overexpression of the Hsa21-encoded miR-155 in DS has been reported to increase Aβ production via the downregulation of sorting nexin 27, a membrane-trafficking component found in early endosomes, that modulates γ-secretase activity (Wang et al., [@B272], [@B271]).

Hsa21 also encodes genes involved in post-translational histone modification, including *DYRK1A, ETS2, HMGN1, BRWD1*, and *RUNX1* (Dekker et al., [@B63]), which may be investigated for their potential roles leading to the aberrant histone modifications observed in AD (Zhang et al., [@B292]; Narayan et al., [@B184]). Histone methylation (specifically H3K4me3) has been shown to correlate highly with genome-wide domains of dysregulated gene expression in DS, which are highly conserved between humans and Ts65Dn mice (Letourneau et al., [@B143]). DS mouse models therefore model epigenetic structures in humans and may be used to study the effects of its dysregulation in AD-DS.

Finally, mouse model research must be undertaken in parallel with other rapid advances in the AD-DS field. The advent of human induced pluripotent stem (iPS) cells (Hunsberger et al., [@B110]) for DS provides for the first time a trisomic human *in vitro* model that recapitulates hallmarks of some AD pathology (Shi et al., [@B242]; Chang et al., [@B37]; Moore et al., [@B175]; Murray et al., [@B179]). The further development of this technology (Hunsberger et al., [@B110]) will prove valuable to phenotyping and drug target discovery, alongside *in vivo* research and *in vitro* primary cultures from DS mice. An increasing call is being made for partnerships to build up large cohorts of, and biobanks from, people with DS for the systematic longitudinal study of AD-DS progression (Hartley et al., [@B97]). In-depth phenotypic studies across development with infants and adults with DS are already underway (Wiseman et al., [@B280]). These will allow greater power to identify biomarkers for the prediction of AD in this large, genetically well-defined population, for example, through plasma (Dekker et al., [@B62]; Schupf et al., [@B232]), cerebrospinal fluid (Portelius et al., [@B201],[@B202]), and neuroimaging studies (Beacher et al., [@B10]; Landt et al., [@B138]; Powell et al., [@B203]; Sabbagh et al., [@B222]). Biomarker studies are also being performed in AD models, including at very early phases of Aβ deposition (Maia et al., [@B158]). Extending these studies to mouse models of DS and AD-DS will contribute to elucidating the genotype-phenotype relationships that ultimately lead to dementia.
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